Next generation flow cytometry for MRD detection in patients with AL amyloidosis
Efstathios Kastritis, Ioannis V. Kostopoulos, Foteini Theodorakakou, Despina Fotiou, Maria Gavriatopoulou, Magdalini Migkou, Maria Irini Tselegkidi, Μαρία Ρούσσου, Alexandra Papathoma, Evangelos Eleutherakis-Papaioakovou, Ioanna Dialoupi, Nikolaos Kanellias, Argyrios Ntalianis, Pantelis Rousakis, Ioannis P. Trougakos, Ourania Tsitsilonis, Charikleia Gakiopoulou, Evangelos Terpos, Meletios Α. Dimopoulos
Abstract
The treatment of AL amyloidosis aims to eradicate the plasma cell clone and eliminate toxic free light chain production. Only in a minority of patients the plasma cell clone is completely eradicated; residual light chain production may still exist while clonal relapse may occur. We used sensitive next-generation flow cytometry (NGF) to detect minimal residual disease (MRD) in AL amyloidosis patients at complete haematologic response. MRD evaluation was feasible in 51 of 52 (98%) tested patients and at a median sensitivity of 2.3 × 10−6 MRD was undetectable in 23 (45%). An organ response occurred in 86% of MRDneg vs 77% in MRDpos; renal response in 15/17(88%) of MRDneg vs in 14/16(87.5%) of MRDpos and cardiac response in 10/10(100%) of MRDneg vs 11/15(73%) of MRDpos patients. After a median follow-up of 24 months post MRD testing, no MRDneg patient had a haematologic relapse vs 6/28(21%) MRDpos (p = .029). Pooling haematologic and organ progressions, 9 (32%) MRDpos patients had disease progression vs only 1 (4%) MRDneg patient (p = .026). In conclusion, MRD detection using NGF has profound clinical implications, so that AL patients with undetectable MRD have a very high probability of organ response and a very low probability of haematologic relapse.